An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

Satya @ JPM 2024

Satya had meetings with potential partners and collaborators to discuss its portfolio of programs during the JPM. A number of programs and collaboration ideas were discussed and would expand our agenda for 2024 and beyond.

Scroll to Top